Astellas has teamed up with Adaptimmune to develop allogeneic chimeric antigen receptor T-cell (CAR-T) and T-cell receptor (TCR) therapies. The agreement sees Astellas pay $50 million (€45 million) upfront and commit to many times as much in milestones to work with Adaptimmune to identify targets and develop cell therapies against them. Through the collaboration, Adaptimmune will use its target identification and validation capabilities to help pick out up to three targets that are outside of the scope of its other projects. Source: Fierce: Biotech 14/1/2020